Affiliations 

  • 1 Monash University Malaysia, School of Pharmacy, Novel Bacteria and Drug Discovery Research Group (NBDD), Selangor Darul Ehsan, Malaysia; Monash University Malaysia, Jeffrey Cheah School of Medicine and Health Sciences, Biomedical Research Laboratory, Selangor Darul Ehsan, Malaysia; Monash University Malaysia, School of Pharmacy, Biofunctional Molecule Exploratory Research Group (BMEX), Bandar Sunway, Malaysia
  • 2 University of Malaya, Faculty of Science, Institute of Biological Sciences, Division of Genetics and Molecular Biology, Malaysia
  • 3 Universiti Kebangsaan Malaysia, UKM Medical Centre, UKM Medical Molecular Biology Institute (UMBI), Kuala Lumpur, Malaysia
  • 4 University of Malaya, Faculty of Science, Institute of Biological Sciences, Division of Genetics and Molecular Biology, Malaysia; Vice Chancellor Office, Jiangsu University, Zhenjiang 212013, PR China
  • 5 Monash University Malaysia, School of Pharmacy, Novel Bacteria and Drug Discovery Research Group (NBDD), Selangor Darul Ehsan, Malaysia; Monash University Malaysia, School of Pharmacy, Biofunctional Molecule Exploratory Research Group (BMEX), Bandar Sunway, Malaysia; University of Phayao, School of Pharmaceutical Sciences, Center of Health Outcomes Research and Therapeutic Safety (Cohorts), Phayao, Thailand; Monash University Malaysia, Global Asia in the 21st Century (GA21) Platform, Health and Well-being Cluster, Implementation and Clinical Outcomes (PICO), Asian Centre for Evidence Synthesis in Population, Bandar Sunway, Malaysia
  • 6 Monash University Malaysia, School of Pharmacy, Novel Bacteria and Drug Discovery Research Group (NBDD), Selangor Darul Ehsan, Malaysia; Monash University Malaysia, Jeffrey Cheah School of Medicine and Health Sciences, Biomedical Research Laboratory, Selangor Darul Ehsan, Malaysia; Monash University Malaysia, School of Pharmacy, Biofunctional Molecule Exploratory Research Group (BMEX), Bandar Sunway, Malaysia; University of Phayao, School of Pharmaceutical Sciences, Center of Health Outcomes Research and Therapeutic Safety (Cohorts), Phayao, Thailand; Monash University Malaysia, Global Asia in the 21st Century (GA21) Platform, Health and Well-being Cluster, Implementation and Clinical Outcomes (PICO), Asian Centre for Evidence Synthesis in Population, Bandar Sunway, Malaysia. Electronic address: lee.learn.han@monash.edu
Braz J Microbiol, 2018 02 02;49(2):207-209.
PMID: 29428207 DOI: 10.1016/j.bjm.2017.04.012

Abstract

Streptomycetes remain as one of the important sources for bioactive products. Isolated from the mangrove forest, Streptomyces gilvigriseus MUSC 26T was previously characterised as a novel streptomycete. The high quality draft genome of MUSC 26T contained 5,213,277bp with G+C content of 73.0%. Through genome mining, several gene clusters associated with secondary metabolites production were revealed in the genome of MUSC 26T. These findings call for further investigations into the potential exploitation of the strain for production of pharmaceutically important compounds.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.